Evaluation of five glycoprotein tumour markers (CEA, CA-50, CA-19-9, CA-125, CA-15-3) for the prognosis of renal-cell carcinoma

Grankvist, Kjell; Ljungberg, Börje; Rasmuson, Torgny

doi:10.1002/(sici)1097-0215(19970422)74:2<233::aid-ijc17>3.0.co;2-e

Cited by 29 publications

(13 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study also confirmed a positive association between CA 125 expression and tumor stage and grade, in accordance with the Grankvist et al results [15]. In our study, only 9.6% of patients had increased serum levels of this marker, especially subjects with advanced disease.…”

Section: Discussionsupporting

confidence: 93%

“…Grankvist et al [15] reported, for the first time, elevated levels of CA 125 in patients with RCC. CA 125 serum levels were particularly increased in patients with high grade tumors and advanced disease, and at multivariate analysis this biomarker resulted in an independent prognostic factor for overall survival.…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, a higher MUC1 expression was shown to be correlated with the metastatic status of patients. Grankvist et al [15] reported elevated serum levels of CA 15-3 in up to 30% of patients in the most advanced clinical stage and grade but failed to identified this tumor marker as an independent prognostic factor for survival at multivariate analysis. Similarly, Briasoulis et al reported abnormal serum levels of this protein in 23% of RCC patients with metastatic disease [29].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Diagnostic and Prognostic Role of Preoperative Circulating CA 15-3, CA 125, and Beta-2 Microglobulin in Renal Cell Carcinoma

et al. 2014

View full text Add to dashboard Cite

CA 15-3, CA 125 and β-2 microglobulin are three common tumor markers currently used for diagnosis, prognosis, assessment of therapeutic response, and/or to evaluate recurrence in breast and ovarian cancer and malignant lymphoproliferative disorders, respectively. In the present prospective study we assessed the role of these three serum proteins as biomarkers for renal cell carcinoma (RCC), as well as any association between tumor marker levels and clinical-pathological parameters. CA 15-3, CA 125, and β-2 microglobulin were preoperatively measured in 332 patients who underwent nephrectomy for RCC. Estimates of cancer-specific survival (CSS) was calculated according to the Kaplan-Meier method. Multivariate analysis was performed to identify the most significant variables for predicting CSS. Preoperatively, 35.2% (n = 117), 9.6% (n = 32) and 30.4% (n = 101) of the patients had abnormal levels of CA 15-3, CA 125 and β-2 microglobulin, respectively. Statistically significant differences resulted between CA 15-3, CA 125 and β-2 microglobulin values and tumor size, Fuhrman grade, presence of lymph node, and visceral metastases. CSS was significantly decreased for patients with high levels of CA 15-3, CA 125, and β-2 microglobulin (P < 0.0001, P < 0.0001, and P = 0.001, resp.). At multivariate analysis only age, the presence of visceral metastases, and high levels of CA 15-3 were independent adverse prognostic factors for CSS.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Diagnostic and Prognostic Role of Preoperative Circulating CA 15-3, CA 125, and Beta-2 Microglobulin in Renal Cell Carcinoma

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Patients with renal-cell carcinoma and elevated CA 125 levels were found to have a significantly shorter survival time than affected patients with normal levels [7]. In advanced non-small cell lung cancer serum CA 125 level was found to serve as an independent prognostic factor [25] and to be related to poor outcome [26].…”

Section: Discussionmentioning

confidence: 99%

“…Researchers now claim that CA 125 is a non-specific marker of mesothelial stimulation or involvement, and that levels of CA 125 are elevated in several malignant and benign diseases in which the mesothel is stimulated. This is supported by findings of elevated CA 125 levels in patients with gynecological tumors other than ovarian carcinoma (in 32% of patients with active cervical or endometrial cancer) [5], and in patients with nongynecological tumors such as hepatocellular carcinoma, melanoma, pancreatic tumors [6], renal cell carcinoma [7], non-small cell lung cancer [8], breast cancer [9] and gastric carcinoma [10]. The list of benign conditions is large and diverse, including normal pregnancy (CA 125 levels are particularly high in the early first trimester) [11], acute pelvic inflammatory disease [5] and cirrhosis with ascites [6,12].…”

Section: Introductionmentioning

confidence: 88%

Serum CA 125 as a Prognostic Factor in Non-Hodgkin's Lymphoma

Bairey

Blickstein

Stark

et al. 2003

Leukemia & Lymphoma

View full text Add to dashboard Cite

Cancer antigen 125 (CA 125) is a glycoprotein expressed in normal tissues originally derived from coelomic epithelia such as peritoneum, pleura, pericardium, fallopian tubes and endometrium. Serum CA 125 levels are elevated in various benign and malignant conditions that involve stimulation of these tissues. Although elevated levels have been reported in patients with non-Hodgkin's lymphoma (NHL), its role as a prognostic factor remained uncertain. In this study, serum CA 125 levels were measured prospectively in 108 consecutive patients with NHL: at diagnosis in 106, in remission in 39 and at relapse in 7. Levels were elevated in 43% at diagnosis. This finding was associated with advanced disease stage, bulky tumors, bone marrow involvement, extranodal disease (in stages III and IV), occurrence of B symptoms, pleural or peritoneal effusions, high serum LDH levels, high serum beta2 microglobulin (beta2-M) levels, elevated International Prognostic Score, poor performance status and partial or no response to treatment. No difference in CA 125 level was found between the indolent and aggressive lymphomas. Serum CA 125 levels at diagnosis had strong association with event-free and overall survival (p = 0.01 and 0.003, respectively), with the patients with increased levels having worse survival. Patients with high CA 125 levels at diagnosis who achieved remission showed a significant decrease in CA 125 levels in remission. In conclusion, CA 125 is not only a reliable marker for staging and assessing tumor activity in NHL, elevated levels are also predictive of decreased survival.

show abstract

Renal‐cell Carcinoma

2014

View full text Add to dashboard Cite

A significant problem for clinicians who treat cancer is the application of the known determinants of disease outcome to the individual patient. The clinical course can be affected by the inherent properties of the tumor, the host‐related factors, and the treatment applied. Renal‐cell carcinoma (RCC) has the reputation of an individual unpredictable outcome with rare cases of spontaneous tumor regression and extended survival despite the presence of metastases. This unpredictable outcome is determined by the genotypic biological behavior and the tumor‐host interaction. Refinement of our ability to predict the outcome should facilitate the rational choice of treatment alternatives and provide more reliability in the interaction with the patient. In case of RCC the absence of other effective treatment modalities besides surgery, renders these considerations even more important.

show abstract

Evaluation of five glycoprotein tumour markers (CEA, CA-50, CA-19-9, CA-125, CA-15-3) for the prognosis of renal-cell carcinoma

Cited by 29 publications

References 17 publications

Diagnostic and Prognostic Role of Preoperative Circulating CA 15-3, CA 125, and Beta-2 Microglobulin in Renal Cell Carcinoma

Diagnostic and Prognostic Role of Preoperative Circulating CA 15-3, CA 125, and Beta-2 Microglobulin in Renal Cell Carcinoma

Serum CA 125 as a Prognostic Factor in Non-Hodgkin's Lymphoma

Renal‐cell Carcinoma

Contact Info

Product

Resources

About